MCID: PRM294
MIFTS: 45

Primary Sjögren Syndrome

Categories: Bone diseases, Immune diseases, Rare diseases

Aliases & Classifications for Primary Sjögren Syndrome

MalaCards integrated aliases for Primary Sjögren Syndrome:

Name: Primary Sjögren Syndrome 59
Primary Sjögren-Gougerot Syndrome 59
Sjogrens Syndrome Primary 55

Classifications:



External Ids:

Orphanet 59 ORPHA289390

Summaries for Primary Sjögren Syndrome

MalaCards based summary : Primary Sjögren Syndrome, also known as primary sjögren-gougerot syndrome, is related to sjogren syndrome and lupus erythematosus. An important gene associated with Primary Sjögren Syndrome is TROVE2 (TROVE Domain Family Member 2), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Pilocarpine and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and lung, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Primary Sjögren Syndrome

Diseases in the Sjogren Syndrome family:

Sjogren's Syndrome, Juvenile, Secondary to Autoimmune Disease Primary Sjögren Syndrome

Diseases related to Primary Sjögren Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
# Related Disease Score Top Affiliating Genes
1 sjogren syndrome 30.7 B2M HSPG2 LTF SPTAN1 TNFSF13B TRIM21
2 lupus erythematosus 29.9 CALR CD40LG IL10 TRIM21 TROVE2
3 celiac disease 1 29.6 CALR CD79A IL10
4 lymphoma, non-hodgkin, familial 29.4 B2M CD79A FAS IL2RA TNFSF13B
5 connective tissue disease 29.4 CD40LG IL10 RNPC3 TNFSF13B
6 systemic lupus erythematosus 28.7 CALR CD40LG CD79A FAS IL10 IL2RA
7 neonatal lupus erythematosus 10.2 SPTAN1 TRIM21
8 hyperlucent lung 10.2 IL10 IL2RA
9 hyperglobulinemic purpura 10.2 HSPG2 TRIM21
10 immunodeficiency with hyper-igm, type 4 10.2 CD40LG TNFSF13B
11 autoimmune pancreatitis 10.2 IL10 SPTAN1 TNFSF13B
12 cow milk allergy 10.2 CD79A IL10
13 xerophthalmia 10.2 HSPG2 TRIM21
14 c1q nephropathy 10.2 CD40LG CD79A
15 immunoglobulin g deficiency 10.2 CD40LG CD79A
16 cryofibrinogenemia 10.2 CD40LG CD79A
17 heparin-induced thrombocytopenia 10.2 CD40LG CD79A
18 immunoglobulin a deficiency 1 10.1 CD40LG CD79A
19 clonorchiasis 10.1 CD79A IL10
20 congenital syphilis 10.1 CD40LG CD79A
21 lacrimal apparatus disease 10.1 HSPG2 IL10 TRIM21
22 pouchitis 10.1 IL10 LTF
23 secondary syphilis 10.1 CD40LG CD79A
24 immunodeficiency-centromeric instability-facial anomalies syndrome 1 10.1 CD40LG CD79A
25 vogt-koyanagi-harada disease 10.1 FAS IL10 IL2RA
26 ocular toxoplasmosis 10.1 CD40LG CD79A
27 persistent generalized lymphadenopathy 10.1 CD40LG CD79A
28 sporotrichosis 10.1 CD40LG CD79A IL10
29 idiopathic neutropenia 10.1 CD40LG IL10 IL2RA
30 root caries 10.1 CD79A LTF
31 cryoglobulinemia 10.1 CD40LG CD79A TNFSF13B
32 brucellosis 10.1 CD40LG IL10 IL2RA
33 autoimmune lymphoproliferative syndrome 10.1 FAS IL10 IL2RA
34 necatoriasis 10.1 CALR IL10
35 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.1 CD40LG IL10 IL2RA
36 toxoplasmosis 10.1 CD40LG CD79A IL10
37 chronic graft versus host disease 10.1 CD79A IL10 IL2RA TNFSF13B
38 acquired immunodeficiency syndrome 10.1 B2M IL10 IL2RA
39 immunodeficiency with hyper-igm, type 1 10.1 CD40LG CD79A
40 solitary osseous plasmacytoma 10.1 B2M CD79A
41 parotitis 10.1 CD79A LTF
42 sialadenitis 10.1 HSPG2 TNFSF13B TRIM21 TROVE2
43 hemorrhagic fever 10.0 B2M CD40LG IL10
44 immune system disease 10.0 CD40LG IL10 TNFSF13B TRIM21
45 heart block, congenital 10.0 CALR TRIM21 TROVE2
46 syphilis 10.0 B2M CD40LG CD79A
47 meningoencephalitis 10.0 B2M CD40LG CD79A
48 rheumatoid arthritis 10.0
49 arthritis 10.0
50 neuropathy 10.0

Graphical network of the top 20 diseases related to Primary Sjögren Syndrome:



Diseases related to Primary Sjögren Syndrome

Symptoms & Phenotypes for Primary Sjögren Syndrome

GenomeRNAi Phenotypes related to Primary Sjögren Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 CD79A CHRM3 LTF
2 Decreased viability GR00381-A-3 9.28 CD79A CHRM3 LTF
3 Decreased viability GR00402-S-2 9.28 CD79A CHRM3 LTF

MGI Mouse Phenotypes related to Primary Sjögren Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.14 B2M CD40LG CD79A FAS HSPG2 IL10
2 cellular MP:0005384 10.13 B2M CALR CD40LG CD79A FAS HSPG2
3 homeostasis/metabolism MP:0005376 10.11 B2M CALR CD40LG CD79A CHRM3 FAS
4 cardiovascular system MP:0005385 10.06 B2M CALR CD40LG CHRM3 FAS HSPG2
5 immune system MP:0005387 10.06 B2M CD40LG CD79A FAS HSPG2 IL10
6 integument MP:0010771 9.8 B2M CD40LG FAS HSPG2 IL10 TRIM21
7 liver/biliary system MP:0005370 9.7 B2M CD79A CHRM3 FAS HSPG2 IL10
8 nervous system MP:0003631 9.61 B2M CALR CD40LG CD79A CHRM3 FAS
9 renal/urinary system MP:0005367 9.1 CD40LG CD79A CHRM3 FAS TRIM21 TROVE2

Drugs & Therapeutics for Primary Sjögren Syndrome

Drugs for Primary Sjögren Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pilocarpine Approved, Investigational Phase 4 54-71-7, 92-13-7 5910
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
5
Cyclophosphamide Approved, Investigational Phase 4 6055-19-2, 50-18-0 2907
6 sodium fluoride Approved Phase 4,Not Applicable 7681-49-4
7
Allantoin Approved Phase 4,Not Applicable 97-59-6 204
8
Betaine Approved, Nutraceutical Phase 4,Not Applicable 107-43-7 247
9
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 77-92-9 311
10
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Not Applicable 8001-79-4
11 Gallopamil Investigational Phase 4 16662-47-8
12 Muscarinic Agonists Phase 4
13 Peripheral Nervous System Agents Phase 4,Phase 2
14 Autonomic Agents Phase 4,Phase 2
15 Cholinergic Agents Phase 4
16 Neurotransmitter Agents Phase 4
17 Calcineurin Inhibitors Phase 4,Phase 2
18 Anti-Ulcer Agents Phase 4
19 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
20 Antineoplastic Agents, Hormonal Phase 4,Phase 2
21 Hormones Phase 4,Phase 2
22 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1
23 glucocorticoids Phase 4,Phase 2
24 Dermatologic Agents Phase 4,Phase 2,Not Applicable
25 Cyclosporins Phase 4,Phase 2
26 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Antifungal Agents Phase 4,Phase 2
29 Hormone Antagonists Phase 4,Phase 2
30 Anti-Inflammatory Agents Phase 4,Phase 2
31 Antacids Phase 4
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2
33 Gastrointestinal Agents Phase 4,Phase 2
34 Calcium, Dietary Phase 4,Not Applicable
35 Listerine Phase 4,Not Applicable
36 Anticoagulants Phase 4,Not Applicable
37 Chelating Agents Phase 4,Phase 1
38 Fluorides Phase 4,Not Applicable
39 Citrate Phase 4,Not Applicable
40 Aloe Phase 4
41 Laxatives Phase 4
42 Castor Phase 4,Not Applicable
43 Carbopol 940 Phase 4,Not Applicable
44 Cathartics Phase 4
45 Vaccines Phase 4
46
Hydroxychloroquine Approved Phase 3 118-42-3 3652
47
Abatacept Approved Phase 3,Phase 2 332348-12-6 10237
48 Antiprotozoal Agents Phase 3
49 Antiparasitic Agents Phase 3
50 Antimalarials Phase 3

Interventional clinical trials:

(show top 50) (show all 68)
# Name Status NCT ID Phase Drugs
1 Effect of Pilocarpine in Patients With Xerostomia Unknown status NCT02982577 Phase 4 Pilocarpine
2 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
3 Quality of Life and Sjögren Syndrome Completed NCT03578900 Phase 4 Xeros;Citric Acid based Mouthwash
4 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
5 Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Recruiting NCT03540823 Phase 4
6 Immune Profile of Saliva and Serum of Patients With Primary Sjögren´s Syndrome Not yet recruiting NCT03711214 Phase 4
7 Efficacy of Tocilizumab in Primary Sjögren's Syndrome. Unknown status NCT01782235 Phase 2, Phase 3 Tocilizumab;Placebo
8 Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome Completed NCT00632866 Phase 3 Hydroxychloroquine;Placebo
9 Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome Completed NCT01601028 Phase 3 Hydroxychloroquine;Placebo
10 Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome Recruiting NCT02067910 Phase 3 Abatacept SC
11 A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome Active, not recruiting NCT02915159 Phase 3
12 Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies Not yet recruiting NCT03700138 Phase 3 Privigen® 100mg/ml at the dose of 2g/kg of body weight;NaCl 0,9%
13 Acupuncture for Primary Sjögren Syndrome Unknown status NCT02691377 Phase 2
14 Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS) Unknown status NCT00953485 Phase 1, Phase 2
15 A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome Completed NCT02464319 Phase 2 hrIL-2 active;hrIL-2 placebo
16 Low Dose Cyclosporin A in Primary Sjögren Syndrome Completed NCT01693393 Phase 2 Cyclosporine A
17 PD of VAY736 in Patients With Primary Sjögren's Syndrome Completed NCT02149420 Phase 2 VAY736;Placebo
18 Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome Completed NCT02775916 Phase 2 CDZ173;Placebo
19 A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome Completed NCT02334306 Phase 2
20 Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome Completed NCT02291029 Phase 2 CFZ533 active - Cohort 1;CFZ533 placebo- Cohort 1;CFZ533 active - Cohort 2;CFZ533 placebo - Cohort 2;CFZ533 active -Cohort 3;CFZ533 active - Cohort 3
21 Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome Completed NCT00426543 Phase 2 MabThera (rituximab);Rituximab, Mabthera
22 A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome Completed NCT02701985 Phase 2 Placebo;RO5459072
23 A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome Completed NCT03247686 Phase 2 RSLV-132;Placebo
24 Fatigue and Interleukin-1 (IL-1) Blockade in Primary Sjøgrens Syndrome Completed NCT00683345 Phase 2 Anakinra;Placebo
25 Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome Completed NCT00391924 Phase 2 Dehydroepiandrosterone
26 Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome Completed NCT01008982 Phase 2 LimphoStat-B
27 Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome Completed NCT01160666 Phase 2 Belimumab
28 A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome Completed NCT00852839 Phase 2 Placebo;552-02
29 Rituximab Treatment in Sjogren's Syndrome Completed NCT00363350 Phase 1, Phase 2 rituximab (anti-CD20)
30 A Study of INCB050465 in Primary Sjögren's Syndrome Recruiting NCT03627065 Phase 2 INCB050465
31 Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome Recruiting NCT03226444 Phase 1, Phase 2 0.005% Lacripep;0.01% Lacripep;Placebo
32 Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS) Recruiting NCT02962895 Phase 2
33 Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome Active, not recruiting NCT02631538 Phase 2 Belimumab;Rituximab;Placebo belimumab;Placebo rituximab
34 UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome Terminated NCT02610543 Phase 2 UCB5857;Placebo
35 Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects Terminated NCT01316770 Phase 2 Dexamethasone Parotid Irrigation;Placebo Parotid Irrigation
36 Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome Terminated NCT02843659 Phase 2 BMS-931699;BMS-986142;Placebo
37 Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome Terminated NCT01552681 Phase 2
38 Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome Withdrawn NCT02495129 Phase 1, Phase 2 VAY736 lower dose;VAY736 higher dose
39 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS) Withdrawn NCT03239600 Phase 2 GSK2618960 2 mg/kg;Placebo;Methotrexate
40 Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study Withdrawn NCT02027298 Phase 2 Abatacept
41 Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome Completed NCT00542763 Phase 1 Mycophenolate sodium
42 A PH I Pilot Imaging Study to Evaluate Molecular Imaging Methods in HVs and pSS Pts Completed NCT02899377 Phase 1
43 Anti-CD20 Antibody Therapy for Sjogren's Syndrome Completed NCT00101829 Phase 1 Rituximab
44 the Effect of HCG Treatment as a Cardiovascular Disease Morbidity Factor in Sjogren Syndrome Patients Unknown status NCT02381587
45 Confocal Microscopy and Lacrimal Gland in Sjogren's Syndrome Unknown status NCT00920179
46 Exercise in Sjogren, Myositis and Takayasu's Arteritis Unknown status NCT01501019 Not Applicable
47 Neurotrophins Implications in Primary Sjögren Syndrome Completed NCT01081184
48 Resistance Exercise in Woman With Primary Sjörgen Syndrome. Completed NCT03130062 Not Applicable
49 Primary Sjögren Syndrome Completed NCT01989819
50 A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome Completed NCT02422407

Search NIH Clinical Center for Primary Sjögren Syndrome

Genetic Tests for Primary Sjögren Syndrome

Anatomical Context for Primary Sjögren Syndrome

MalaCards organs/tissues related to Primary Sjögren Syndrome:

41
Eye, Salivary Gland, Lung, B Cells, Brain, T Cells, Colon

Publications for Primary Sjögren Syndrome

Articles related to Primary Sjögren Syndrome:

(show top 50) (show all 167)
# Title Authors Year
1
Constrictive Bronchiolitis in Patients With Primary Sjögren Syndrome. ( 29596206 )
2018
2
Overactive bladder symptom bother and health-related quality of life in patients with systemic lupus erythematosus and primary Sjögren syndrome. ( 30419773 )
2018
3
Mucosal-associated Lymphoid Tissue (MALT) Lymphoma in Association With Pediatric Primary Sjogren Syndrome: 2 Cases and Review. ( 30371536 )
2018
4
Biopsy-proven renal involvement and prognosis in 13 hispanic patients with primary Sjögren syndrome. ( 28864093 )
2018
5
Cutaneous features and diagnosis of primary Sjögren syndrome: An update and review. ( 29787840 )
2018
6
Diagnostic dilemma between sarcoidosis and primary Sjögren syndrome: mimicry, concomitance or coincidence? An up-to-date clinician's perspective. ( 30079897 )
2018
7
Prevalence, severity, and predictors of dry eye and dry mouth in Chinese patients with primary Sjögren syndrome. ( 30094749 )
2018
8
Case report of primary Sjögren Syndrome with simple trigeminal lesion as initial symptom. ( 30170790 )
2018
9
Athetoid Movements as Initial Manifestation of Primary Sjögren Syndrome. ( 30191088 )
2018
10
Anti-DNase I Antibody: A New Serological Reactivity in Primary Sjögren Syndrome. ( 30273262 )
2018
11
Tear Meniscus and Corneal Sub-basal Nerve Plexus Assessment in Primary Sjögren Syndrome and Sicca Syndrome Patients. ( 30379721 )
2018
12
Association between systemic activity ındex and dry eye severity in patients with primary Sjögren syndrome. ( 30403265 )
2018
13
Recurrent Cerebral Infarctions in Primary Sjögren Syndrome: A Case Report and Literature Review. ( 30459702 )
2018
14
Combined disease with pulmonary arterial hypertension and pulmonary venous hypertension revealed after treatment of heart failure with preserved ejection fraction in a case with primary Sjögren syndrome. ( 26052802 )
2018
15
Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement. ( 28324200 )
2017
16
Incidence and Mortality of Physician-Diagnosed Primary Sjögren Syndrome: Time Trends Over a 40-Year Period in a Population-Based US Cohort. ( 28389066 )
2017
17
Primary Sjögren Syndrome With Pleural Effusion. ( 28413082 )
2017
18
Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. ( 28416003 )
2017
19
Impact of pain on cognitive functions in primary Sjögren syndrome with small fiber neuropathy: 10 cases and a literature review. ( 28422829 )
2017
20
Erratum to: Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement. ( 28444575 )
2017
21
Extended high-frequency audiometry as early detection of hearing loss in primary Sjögren syndrome. ( 28744788 )
2017
22
Erratum Regarding "AJKD Atlas of Renal Pathology: Kidney Disease in Primary Sjögren Syndrome" (Am J Kidney Dis. 2017;69[6]:e29-e30). ( 28760334 )
2017
23
Hypokalemic Paralysis due to Primary Sjögren Syndrome: Case Report and Review of the Literature. ( 28835864 )
2017
24
Primary Sjögren syndrome that initially presented with repeated hypergammaglobulinemic purpura after prolonged sitting: A case report. ( 29390329 )
2017
25
B Cell Depletion Therapy Normalizes Circulating Follicular Th Cells in Primary Sjögren Syndrome. ( 28042126 )
2017
26
Acupuncture for Primary Sjögren Syndrome (pSS) on symptomatic improvements: study protocol for a randomized controlled trial. ( 28103850 )
2017
27
Work Disability in Newly Diagnosed Patients with Primary Sjögren Syndrome. ( 28148755 )
2017
28
The Risk of Deep Venous Thrombosis and Pulmonary Embolism in Primary Sjögren Syndrome: A General Population-based Study. ( 28298559 )
2017
29
Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. ( 25433020 )
2016
30
Renal involvement in primary Sjögren syndrome. ( 26568188 )
2016
31
Sjögren SER: National registry of the Spanish Society of Rheumatology of patients with primary Sjögren syndrome: Objectives and methodology. ( 26617051 )
2016
32
Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary Sjögren syndrome: comparison of different kits. ( 26659716 )
2016
33
Tubulointerstitial nephritis in primary Sjögren syndrome: clinical manifestations and response to treatment. ( 26728714 )
2016
34
Serologic Markers and Ocular Staining Score in Primary Sjögren Syndrome. ( 26845319 )
2016
35
Risk of Chronic Obstructive Pulmonary Disease in Female Adults With Primary Sjögren Syndrome: A Nationwide Population-Based Cohort Study. ( 26962839 )
2016
36
Severe Thrombocytopenia as Initial Signs of Primary Sjögren Syndrome in a 9-Year-Old Female. ( 27003329 )
2016
37
Increased Frequency of Hand Osteoarthritis in Patients with Primary Sjögren Syndrome Compared with Systemic Lupus Erythematosus. ( 27036385 )
2016
38
Shunt reversal due to deterioration of chloroquine-induced cardiomyopathy in a patient with primary Sjögren syndrome. ( 27111180 )
2016
39
Recurrent Attacks of Hypokalemic Quadriparesis: An Unusual Presentation of Primary Sjögren Syndrome. ( 27374687 )
2016
40
Treatment of primary Sjögren syndrome. ( 27411907 )
2016
41
Multiobserver Reliability of Ultrasound Assessment of Salivary Glands in Patients with Established Primary Sjögren Syndrome. ( 27528574 )
2016
42
Women With Primary Sjögren Syndrome and With Non-Sjögren Sicca Syndrome Show Similar Vulvar Histopathologic and Immunohistochemical Changes. ( 27532148 )
2016
43
Asymptomatic Atherosclerosis in Primary Sjögren Syndrome: Correlation Between Low Ankle Brachial Index and Autoantibodies Positivity. ( 27556236 )
2016
44
Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects. ( 27844414 )
2016
45
Virtual Touch Quantification of the Salivary Glands for Diagnosis of Primary Sjögren Syndrome. ( 27872417 )
2016
46
Erratum to: Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects. ( 27905085 )
2016
47
Limb weakness and pain in a patient with primary Sjögren syndrome. ( 27905310 )
2016
48
Answer to Photo Quiz: Limb weakness and pain in a patient with primary Sjögren syndrome. ( 27905311 )
2016
49
Connective tissue diseases: Refining the classification criteria for primary Sjögren syndrome. ( 27994222 )
2016
50
Orbital Myositis and Primary Sjögren Syndrome. ( 26233955 )
2015

Variations for Primary Sjögren Syndrome

Expression for Primary Sjögren Syndrome

Search GEO for disease gene expression data for Primary Sjögren Syndrome.

Pathways for Primary Sjögren Syndrome

Pathways related to Primary Sjögren Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 B2M CALR CD40LG CD79A IL10 IL2RA
2
Show member pathways
12.91 B2M CD40LG IL10 IL2RA SPTAN1 TNFSF13B
3
Show member pathways
12.62 CD40LG CD79A FAS TNFSF13B TRB
4
Show member pathways
12.3 B2M CALR CD40LG FAS IL10 IL2RA
5
Show member pathways
12.11 CD40LG CD79A IL10 IL2RA TRB
6
Show member pathways
12.03 CD40LG FAS IL10 TRB
7 11.68 B2M CD40LG CD79A FAS IL10 IL2RA
8 11.67 CD79A IL10 IL2RA
9
Show member pathways
11.63 B2M IL2RA TRB
10 10.88 B2M CALR

GO Terms for Primary Sjögren Syndrome

Cellular components related to Primary Sjögren Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.91 B2M CALR CD40LG HSPG2 IL10 LTF
2 extracellular region GO:0005576 9.81 B2M CALR CD40LG FAS HSPG2 IL10
3 specific granule lumen GO:0035580 9.5 B2M LTF SPTAN1
4 tertiary granule lumen GO:1904724 9.43 B2M LTF SPTAN1
5 external side of plasma membrane GO:0009897 9.35 B2M CALR CD40LG CD79A IL2RA
6 cell surface GO:0009986 9.1 B2M CALR CD40LG FAS IL2RA LTF

Biological processes related to Primary Sjögren Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.8 B2M CD79A IL2RA LTF TNFSF13B
2 B cell differentiation GO:0030183 9.54 CD40LG CD79A IL10
3 positive regulation of T cell proliferation GO:0042102 9.5 CD40LG IL2RA TNFSF13B
4 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.46 B2M CALR
5 response to molecule of bacterial origin GO:0002237 9.43 B2M IL10
6 positive regulation of cell cycle GO:0045787 9.43 CALR IL10 TRIM21
7 immunoglobulin secretion GO:0048305 9.16 CD40LG TNFSF13B
8 B cell proliferation GO:0042100 9.13 CD40LG CD79A IL10
9 immune response GO:0006955 9.1 B2M CD40LG FAS IL10 IL2RA TNFSF13B

Sources for Primary Sjögren Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....